Predict your next investment

Corporation
HEALTHCARE | Medical Devices & Equipment / Imaging & Diagnostic Equipment
magellanbio.com

See what CB Insights has to offer

Founded Year

2004

Stage

Acquired | Acquired

Total Raised

$34M

About Magellan Biosciences

Magellan Diagnostics is a medical device company. The company develops and manufactures point-of-care systems, clinical laboratory instruments, and analytical laboratory services focused on lead testing.

Magellan Biosciences Headquarter Location

101 Billerica Ave Building 4

North Billerica, Massachusetts, 01862,

United States

978-856-2345

Latest Magellan Biosciences News

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Meridian Bioscience, Inc. - VIVO

Dec 12, 2017

Share this article NEW YORK, Dec. 12, 2017 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Meridian Bioscience, Inc. ("Meridian" or the "Company") (NASDAQ:   VIVO ). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980. The investigation concerns whether Meridian and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. On March 24, 2016, Meridian announced the acquisition of Magellan Biosciences, Inc. and its wholly-owned subsidiary Magellan Diagnostics, Inc. (together "Magellan"). Magellan provides point-of-care lead testing systems for the testing of blood to diagnose lead poisoning in children and adults. On May 17, 2017, the U.S. Food and Drug Administration ("FDA") issued a press release "warning Americans that certain lead tests manufactured by Magellan Diagnostics may provide inaccurate results. "  On this news, Meridian's share price fell $1.30, or 8.81%, to close at $13.45 on May 17, 2017. On July 13, 2017, the FDA announced that it had observed several potential violations of federal law during a recent inspection of Magellan's facility in North Billerica, Massachusetts. The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com . CONTACT:

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Magellan Biosciences

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Magellan Biosciences is included in 2 Expert Collections, including Medical Devices.

M

Medical Devices

7,884 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

H

Health Monitoring & Diagnostics

701 items

Companies developing technology to facilitate near-patient and point-of-care (POC) in vitro diagnostic testing. Companies tagged as #NearPatient&POCTesting

Magellan Biosciences Patents

Magellan Biosciences has filed 1 patent.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

9/30/2010

7/31/2012

Quantum mechanics, Gas technologies, Industrial gases, Quantum measurement, Lead poisoning

Grant

Application Date

9/30/2010

Grant Date

7/31/2012

Title

Related Topics

Quantum mechanics, Gas technologies, Industrial gases, Quantum measurement, Lead poisoning

Status

Grant

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.